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Abstract: Triple negative breast cancers (TNBCs) are molecularly heterogeneous, and the link between
their aggressiveness with African ancestry is not established. We investigated primary TNBCs for
gene expression among self-reported race (SRR) groups of African American (AA, n = 42) and
European American (EA, n = 33) women. RNA sequencing data were analyzed to measure changes
in genome-wide expression, and we utilized logistic regressions to identify ancestry-associated gene
expression signatures. Using SNVs identified from our RNA sequencing data, global ancestry was
estimated. We identified 156 African ancestry-associated genes and found that, compared to SRR,
quantitative genetic analysis was a more robust method to identify racial/ethnic-specific genes that
were differentially expressed. A subset of African ancestry-specific genes that were upregulated in
TNBCs of our AA patients were validated in TCGA data. In AA patients, there was a higher incidence
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of basal-like two tumors and altered TP53, NFB1, and AKT pathways. The distinct distribution
of TNBC subtypes and altered oncologic pathways show that the ethnic variations in TNBCs are
driven by shared genetic ancestry. Thus, to appreciate the molecular diversity of TNBCs, tumors
from patients of various ancestral origins should be evaluated.
Keywords: triple negative breast cancer; African ancestry; RNAseq analysis; oncologic
pathways; disparities
1. Introduction
According to national surveillance data for the United States (US), non-white minority populations
suffer higher mortality rates for most cancers [1]. This has largely been considered a consequence of
poor health care equity and/or access [2,3] related to the prevalence of lower socioeconomic status (SES)
for minority populations. However, European Americans (EAs) have historically been diagnosed with
a higher incidence of breast cancer, compared to African Americans (AAs). Prior to the mid-1980s,
breast cancer mortality rates for these self-reported race (SRR) groups was essentially the same, but
then diverged in subsequent years. These persistent survival disparities are currently about 40% [1,4]
and occur independent of SES, which suggests there are additional factors, including biology, leading
to race-group differences in mortality.
The onset of race-group mortality rate disparities coincides with the advent of hormone-targeted
therapies [5] that are now standard-of-care for hormone receptor-positive tumors. Compared to women
of European descent, AA women [4,6–13] and women of African descent world-wide [9,14–16] have a
higher incidence of triple-negative breast cancer (TNBC) [17–21], which is characterized by the absence
of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2
(HER2). Therefore, in the context of standardizing ER/PR- and HER2-targeted therapies, the divergence
of AA vs. EA mortality likely unmasked population-level differences in tumor biology, which we
have previously shown to correlate with genetic ancestry [22]. Several epidemiological studies suggest
that genetic ancestry is a factor in the etiology of specific tumor phenotypes [13,23–25], with disease
outcomes based upon molecular phenotype (e.g., HR status) directly affecting treatment decisions,
regardless of SES barriers to high-quality clinical care.
TNBC, one of the most aggressive forms of breast cancer, has limited treatment options that
are ineffective when the cancer is diagnosed at later stages [25–29]. Since AA women tend to be
diagnosed at later stages [30,31], at an early age [32–34], and suffer higher rates of TNBC, these factors
likely contribute to AAs having the highest breast cancer mortality rate among all race groups. Even
within TNBC cases, AA women have a higher mortality compared to EA women [4], and these
race-/ethnicity-associated differences in TNBC survival suggest that there is a difference in disease
progression, which may be driven by differences in gene expression that are detectable by genomic
investigations. Multiple lines of evidence support this theory, including differences in the prevalence
of “Vanderbilt TNBC subtypes” [35,36] among SRR groups, in which gene expression signatures define
these subtypes. Although this TNBC subtype classification was intended to assist with clinical
management and identification of targetable genes in TNBCs [36], these subtypes represent a myriad
of heterogeneity [37,38] that has yet to be fully defined for understudied/minority populations, who
suffer most from TNBC.
To have better representation of phenotypic variation in TNBC tumors, we report here our
investigation of differences in TNBC primary tumor gene expression using bulk RNAseq, comparing
TNBCs of AAs to those of EAs. As opposed to use of traditional methods identifying differentially
expressed genes (DEGs) between SRR groups, we quantified genetic ancestry (QGA) for individual
patients across five human ancestry super groups, and identified the African ancestry-associated
gene expression signatures of TNBCs. We then determined whether these racial/ethnic differences
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in gene expression reveal insights into biological pathways, and characterized the TNBC subtypes
using a newly revised method for categorizing subtypes, building upon previously validated tools. We
also characterized tumor-associated immune responses for each tumor. Furthermore, we determined
whether phenotypic subtypes were associated with genetic ancestry, as well as whether there were
biases of prevalence of TNBC phenotypes between patient SRR and ancestry groups.
2. Results
2.1. African Ancestry-Associated Gene Signatures in Treatment-Naïve and Post-Treatment TNBCs
In an effort to uncover differentially expressed genes that are driven by shared ancestry, and
therefore presumably under distinct genetic regulation, we first quantified the individual genetic
ancestry of our cohort across five human super-groups. The initial step for this ancestry estimation
included identification of SNVs from the bulk RNAseq data. These variants were compared to the
1000 Genomes super-group reference sets to estimate proportional ancestry and correlated to the
1000 Genomes populations. Specifically, each individual was measured for European [39], East Asian
(EAS), South Asian (SAS), American Native (AMR), and African (AFR) ancestry (Figure 1A). As
expected, most genetic ancestry for EAs was European (86–99%), and most ancestry for AAs was
African (45–98%). However, a portion of the EA patients had appreciable Asian and/or American
Native admixture (2–15%). Similarly, most AA patients had substantial European (0–44%) or American
Native (0–14%) ancestry. This analysis also revealed that, based on the molecular signature of their
tumors, two patients who self-reported as EAs had more than 60% of African ancestry and clustered
with AA patients.
Using the QGA for each individual, we conducted gene-by-gene linear regressions, screening
for significant associations with each of the QGA super-groups. Among all ancestry group tests,
AFR and European ancestry estimations yielded the largest and most significant set of genes with
ancestry-associated expression changes, compared to EAS, SAS, and AMR. For the treatment-naïve
tumors (31 AAs and 29 EAs), 156 genes were significantly associated with African ancestry (adjusted
p-value < 0.05, Table S4). Similarly, we conducted a QGA-association analysis on 15 post-treatment
tumors (residual tumors), but low patient numbers (11 AAs and four EAs) impeded our ability to
reach statistical significance (adjusted p-value threshold < 0.05). Alternatively, we accomplished a
traditional SRR group comparison and found 13 SRR-associated genes in residual tumors that were
not identified in our SRR treatment-naïve analysis (adjusted p-value < 0.05) (Figure S2).
Most ancestry-associated genes showed a negative correlation in expression (downregulation) for
those of African ancestry patients compared to those of European ancestry (Figure 1B). In a two-way
hierarchical clustering of both gene expression and patient samples, SRR groups arbitrarily clustered
together (Figure 1B). Further, when we investigated the phylogenic structure of the patient cluster
nodes, we found that EA patients separated into two distinct groups (Figure 1B, red arrow). The
separate EA groups had differences in gene expression patterns as well as genetic ancestry composition,
with one group primarily containing only European ancestry, and the second group containing a
substantial amount of genetic admixture from EAS, SAS, and AMR. The gene expression patterns of
the admixed EAs were similar to the AA group (Figure 1B), which also had substantial EAS, SAS, and
AMR admixture. Therefore, this separation of EA patients provided further evidence of the impact of
genetic ancestry on gene expression. Using this gene set, a principal component analysis (Figure 1C)
with the African ancestry-associated genes completely segregated the SRR groups, suggesting that
this gene signature from TNBCs predicts race/ancestry among TNBC patients. Because these genes
were selected for their association with African ancestry, and ancestry estimates were highly correlated
with self-identity, we are confident that this set of genes is representative of genes that are distinctly
regulated among race/ethnicity groups, due to individual-level African ancestry.
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Figure 1. Differentially expressed genes (DEGs) associated with quantified genetic ancestry (QGA) in 
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African (AFR, pink). Samples are grouped by treatment status (treatment naïve or residual tumor) 
and self-reported race (SRR). (B) Clustergram heatmap of the 156 (p < 0.05) genes that show 
differential expression levels by QGA, where rows represent genes and columns represent 
individuals. SRR is shown in the top row of the color map (red indicating EA, and blue indicates AA); 
the remaining color map rows indicate ancestry estimations for each individual. The red box indicates 
genes that are associated with non-European admixture (EAS, SAS, and AMR). Constellation plot, 
right, representing the hierarchical structure of the individuals shown at the bottom of the heatmap. 
Red dots indicate SRR EAs; blue dots are SRR AAs. The red arrow points to the substrata of EA 
individuals with increased admixture; this corresponds to the non-European admixture genes in the 
red box of the heatmap. (C) Multidimensional analysis using 156 ancestry-associated genes indicates 
that the expression patterns separate individuals into SRR groups. Red indicates EA, and blue 
indicates AA. The blue arrow indicates an individual that self-reported as EA but has mostly AFR 
ancestry, clustering with the AA group. (D) De novo network analysis using QGA DEGs using 
Ingenuity Pathway Analysis (IPA) software. Molecules in green are upregulated in individuals with 
increased AFR ancestry; those in blue are downregulated in individuals with AFR ancestry. Molecules 
in orange are drawn into the network and predicted to be activated based on the state of DEGs in the 
network, using published interactions from the curated Ingenuity Knowledge Base. Orange lines 
between molecules indicate relationships leading to activation; blue lines indicate relationships 
leading to inhibition. Yellow lines indicate that the relationship between two molecules is not in the 
expected direction. For example, in this network TP53 is known to inhibit AKT1. TP53 is activated, 
and so it is expected that AKT1 would be downregulated. However, it is not. Because of this, the line 
showing the interaction between these two molecules is shown as yellow. 
Since several EA patients had no appreciable African ancestry, we also determined the 
association of European ancestry with gene expression, using the same linear regression model used 
for the African-associated gene selection. As a way of validating the method’s capacity to identify 
ancestry-associated genes, we noted whether the genes associated with European ancestry were 
unique, compared to genes associated with African ancestry. Of the 156 African-associated genes, 153 
overlapped with genes associated with European ancestry; seven additional genes were European-
specific and the remaining three were African-specific (Figure S1C). For the genes shared between 
Figure 1. Differentially expressed genes (DEGs) associated with quantified genetic ancestry (QGA)
in treatment-naïve TNBC RNA-seq. (A) QGA estimates for each cancer case, derived from RNAseq
variants. Geographic ancestry super-group categories are indicated as European (EUR, light blue),
East Asian (EAS, dark blue), American Native (AMR, light green), South Asian (SAS, dark green), and
African (AFR, pink). Samples are grouped by treatment status (treatment naïve or residual tumor) and
self-reported race (SRR). (B) Clustergram heatmap of the 156 (p < 0.05) genes that show differential
expression levels by QGA, where rows represent genes and columns represent individuals. SRR is
shown in the top row of the color map (red indicating EA, and blue indicates AA); the remaining
color map rows indicate ancestry estimations for each individual. The red box indicates genes that are
associated with non-European admixture (EAS, SAS, and AMR). Constellation plot, right, representing
the hierarchical structure of the individuals shown at the bottom of the heatmap. Red dots indicate SRR
EAs; blue dots are SRR AAs. The red arrow points to the substrata of EA individuals with increased
admixture; this corresponds to the non-European admixture genes in the red box of the heatmap. (C)
Multidimensional analysis using 156 ancestry-associated genes indicates that the expression patterns
separate individuals into SRR groups. Red indicates EA, and blue indicates AA. The blue arrow
indicates an individual that self-reported as EA but has mostly AFR ancestry, clustering with the AA
group. (D) De novo network analysis using QGA DEGs using Ingenuity Pathway Analysis (IPA)
software. Molecules in green are upregulated in individuals with increased AFR ancestry; those in
blue are downregulated in individuals with AFR ancestry. Molecules in orange are drawn into the
network and predicted to be activated based on the state of DEGs in the network, using published
interactions from the curated Ingenuity Knowledge Base. Orange lines between molecules indicate
relationships leading to activation; blue lines indicate relationships leading to inhibition. Yellow lines
indicate that the relationship between two molecules is not in the expected direction. For example, in
this network TP53 is known to inhibit AKT1. TP53 is activated, and so it is expected that AKT1 would
be downregulated. However, it is not. Because of this, the line showing the interaction between these
two molecules is shown as yellow.
Since several EA patients had no appreciable African ancestry, we also determined the
association of European ances ry with gene expression, using the ame line r regr ssion model
used for the African- ssociated gene selection. As a way of validating the method’s capacity to
iden ify ancestry-associated genes, we noted whether the genes associat d with European anc s ry
were unique, ompared to genes associat d wi African ancestry. Of e 156 Afric -a sociat d
ge es, 153 overlapped with genes associated with European ancestry; seven additional genes were
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European-specific and the remaining three were African-specific (Figure S1C). For the genes shared
between African and European ancestry, trends of gene expression positively correlated with African
ancestry, but negatively correlated with European ancestry. This contrast suggests that ancestral
informative alleles that are population-private (i.e., existing in one ancestry group and not the other)
are the genetic drivers regulating gene expression levels.
We also determined differences in expression comparing SRR groups of EAs with AAs in order to
compare the results of our genetic ancestry method to the traditional race-group comparison method
(Figure S3). The SRR DEG comparison yielded more than 1000 genes (Figure S3A) with significant
differential expression (adjusted p-value < 0.05; upregulated genes = 266, downregulated genes = 758,
Table S5.). However, hierarchical clustering revealed that the range of gene expression differences for
the SRR DEGs was smaller compared to the QGA-associated genes, translating to higher absolute fold
changes in QGA-associated genes (avg∆ = 2.4) compared to SRR DEGs (avg∆ = 1.14) (Figure S3C).
Compared to the ancestry-associated genes, 81 genes were shared between SRR DEG analysis and
QGA DEG analysis. This suggests that, when comparing SRR groups, less than 8% of the DEGs will be
due to genetic ancestry; the remaining 92% could be due to socio-clinical factors (e.g., comorbidity,
environmental exposures).
2.2. Distinct Biological Networks of African Ancestry and Differentially Expressed Genes
We investigated whether genes that show expression changes associated with African ancestry
are involved in biological pathways that could suggest distinct ancestry-specific functionality. We
calculated the fold-change differences for the 156 African-associated genes between the SRR race groups,
EA and AA, for pathway enrichment analysis. For network predictions, we used Ingenuity Pathway
Analysis (IPA) software [40] (Figure 1D). We conducted a causal network analysis, which assessed
known connections across all African-associated genes to predict how these interactions may have
been altered, based on gene expression changes between the SRR groups. The most prominent network
was derived from 25 genes that were associated with African ancestry, with an additional 10 genes
that were automatically included through knowledgebase predictions, based on previously published
interactions. In the de novo network, canonical cancer-related pathways, including NfKB, TP53,
and EGFR, were involved and predicted to be activated among AA individuals (Figure 1D). Several
interactions within the network were designated “inconsistent” in the context of the established expected
gene regulation effects. An example of these unexpected interactions is central to understanding
how ancestry influences these networks (Figure 1D, red box). For example, TP53 is predicted to be
activated in AAs based on gene expression being higher; however, the expected/established outcome
of TP53 activation would be down-regulation of the AKT1 kinase and IL6 chemokine genes. However,
in our ancestry-related pathway analysis, both genes appeared to be activated when TP53 was
activated. Hence, the African-ancestry associated genes had altered expression, leading to unexpected
relationships inconsistent with previous findings. We also determined the general pathway enrichment
among the African-associated genes; the most significantly enriched pathways are shown in Figure S1C.
An additional pathway analysis, utilizing DEGs from the SRR comparison (Figure S2), also revealed
involvement of canonical cancer-related pathways. As seen in Figure S2E, the top gene ontology
diseases and functions in the de novo system were behavior, cellular assembly and organization, and
connective tissue disorders. A canonical cancer pathway involving the NFkB complex is central to this
network (Figure S2E), which is predicted to activate (denoted by orange relationship lines) various
genes upregulated in the dataset, including the transcription regulator CITED4, peptidase ADAMTS9,
and kinase PIM3.
2.3. Prevalence of TNBC Subtypes across Race and Ancestry Groups
A major caveat to treating TNBC is inherent to its clinical diagnosis being lack of hormone
receptor expression, which indicates that the most effective hormone-targeted therapy would simply
not be beneficial. An effort to determine indications that are actionable includes characterization of
Cancers 2020, 12, 1220 6 of 20
genomic expression signatures, which separate TNBC tumors into molecular subtypes [41]. TNBC
subtypes were initially determined using the Vanderbilt TNBC subtype tool, which functions by
correlating genomic input with pre-determined gene signatures that were discovered in the tool’s
tumor training [42]. The original six Vandy subtypes included mesenchymal (M), immunomodulatory
(IM), luminal androgen receptor positive (LAR), basal-like 1 (BL1), basal-like 2 (BL2), and mesenchymal
stem-cell like (MSL) categories. While two of these categories (IM and MSL) have been retired from
use [43], the tool still designates all six categories, and users are advised to manually re-assign these
based on the second-highest correlated subtype. We first used the suggested manual reassignment
strategy (Figure 2A) and compared subtype distributions between SRR groups. We observed that AAs
had the highest proportions of M and BL1, whereas EAs had primarily BL2 (Figure 2A).
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Figure 2. TNBC subtyping and distribution among SRR and treatment groups. (A) Distribution of
re-assigned TNBC subtype calls across SRR race groups using the Vanderbilt calling method. (B)
Clustergram heatmap of TNBCType call correlations for BL1, BL2, LAR, and M subtypes from use of the
Vanderbilt tool with TPM (transcripts per million) and FPKM (fragments per kilobase of exon model
per million reads mapped) values as input and our TNBC subtyping method (TNHF mean and median).
Rows represent the different subtype correlations for the tools, and columns represent individuals.
Using these correlations, our samples separate into six clusters, numbered at the bottom. Color map
columns of the call reassignments removing IM and MSL are shown at the top of the heatmap (key to
the upper right). Sample names are colored based on their cluster assignment. Reassignment of TNBC
subtypes based on a dual-tool reduction method. Cluster Nodes: 1 = LAR+/BL1−, 2 = M−, 3 = M+,
4 = BL2+/BL1−, 5 = BL1+/BL2−, 6 = Indistinct (IND). (C) Parallel plots for each of the six clusters
showing the correlation for the samples within the cluster to a given TNBC subtyping call/method
(bottom). Cluster coloring matches that in panel 2B. (D) Sankey plot showing how samples reassign
from the original TPM call, to the second most correlated call (for re-assignment of IM, MSL, and
UNS samples) and their cluster assignment from panel B. (E) TNBC clusters (from panel B) and
their distribution among SRR. (F) Total abundance of tumor-associated leukocytes estimated using
CIBERSORT deconvolution methods is shown in comparison to SRR and treatment groups.
We noted that Vandy categories are inherently heterogeneous, as the tumors show positive
correlation with multiple subtypes. Therefore, we created a more data-driven approach using a method,
named the Triple Negative Hetero-Fluid (TNHF) method (described in Methods), which measures
correlation scores (CS) from only the valid TNBC subtype categories, BL1, BL2, M, and LAR and
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incorporates the heterogeneity of these subtypes into specific categories. Specifically, we measured the
relatedness of our TNHF subtype CS with Vandy TNBC CS, using unsupervised clustering (Figure 2B).
Based on the CS patterns, the tumors separated into six cluster nodes, as opposed to the four manually
reassigned categories. The CS patterns of each node revealed heterogenic tumor phenotypes, observed
as a positive or negative CS for a given category, indicating the presence or absence of the genomic
signatures underlying the TNBC subtypes in each tumor (Figure 2C). Therefore, we used a subtype
nomenclature to indicate a positive or negative subtype status to describe the heterogeneity. These
TNHF category nodes were designated as: 1. LAR+/BL1−, 2. M−, 3. M+, 4. BL2+/BL1−, 5. BL1+/BL2−,
and 6. Indistinct (IND—not negatively/positively correlated with any specific subtype) (Figure S4B).
These designations allowed us to stay within the framework of the original TNBC subtypes yet capture
the breadth of heterogeneity within the naturally occurring phenotypes. Subsequent comparisons of
subtypes among the SRR categories now indicated that AAs had the highest occurrence of BL2+/BL1−,
and EAs had the highest occurrence of M−. This change in SRR distributions suggests that manual
reassignment of categories from the Vandy tool is likely not the optimal resolution. As we tracked
how the subtype designations changed from the original tool, through reassignment, ending with
the TNHF category, (Figure 2D), we see that manual reassignments led to a collapse of options that
mis-categorized certain tumors, that the TNFH approach was able to resolve into genomic data-derived
heterogenic subtypes. For instance, Vandy-designated IM tumors were split between LAR and BL2
manual reassignments; however, they were reconnected into the M− TNHF category, which represents
multiple negative correlations (Figure S4B), and a lack of homogeneity to fit any Vanderbilt categories.
Further investigation of the expression signatures in the M− tumor subtypes, perhaps in a single-cell
fashion, is necessary to determine the true biological definition of this tumor subtype.
2.4. Differences in Immune Responses by RNAseq Deconvolution
To investigate immunological differences in our AA-enriched TNBC cohort, we used
CIBERSORT [44], an in silico deconvolution method, to determine the estimated prevalence of
specific immune cell types across the TNBC tumors. We compared proportions of tumor-associated
leukocytes (TAL) across patient strata (SRR, ancestry) (Figure 2E and Figure S5), treatment status
(treatment naïve vs residual) (Figure 2E), and our six TNBC subtype clusters (Figure S5). There were
distinctions of immune responses, defined by the absolute TAL score (Figure S5A). When comparing
high vs low overall TAL scores (adjusted p-value < 0.05), 832 genes showed significant differential
expression, of which 116 genes are included in the TAL algorithm. The remaining genes associated
with TAL scores have contrasting expression across our cohort, indicating significant variation of
these immune-related genes between high vs low TAL groups (Figure S5A). Individual TAL scores
indicate variation of specific immune cell infiltration; however, the low numbers of individuals in each
patient strata precluded our ability to find statistically significant differences, though there are clear
trends of higher TAL scores for EAs compared to AAs and lower TAL scores for in pre-treatment vs
post-treatment (residual) tumors (Figure 2F).
2.5. Potential Druggable Targets from Ancestry-Associated Gene Signatures
As a clinical follow-up to our ancestry-associated gene expression differences, including key
biological distinctions in canonical cancer-related networks across both treatment-naïve and treated
TNBC tumors, we investigated if these genes are potential drug/treatment targets. Specifically,
we performed a search of the literature and www.clinicaltrials.gov to determine if the African
ancestry-associated genes we identified have FDA-targeted therapeutics available or are being studied
in clinical trials for use in any cancer type. We found more than a dozen African ancestry genes that
are currently targeted with FDA-approved drugs, and most of these genes had multiple drug options
(Table 1). To determine if these genes are indeed targets for African American TNBC patients, we first
verified that they were differentially expressed between SRR groups (Figure 3A) and found they were
all significantly different between AA and EA patients. Next, we utilized the TCGA cohort to validate,
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independently, if the TNBC-specific expression differences were replicated in an additional cohort of
patients (Figure 3B). Most of the candidate target genes maintained the same trend; however, statistical
significance was lost for most genes, likely due to the lack of ancestry estimation in TCGA tumors,
thus the confounding impact of mixed ancestry because of possible discordance between SRR and
QGA. However, from our cohort, PIM3, PPP2R4, and ZBTB22 retained significant upregulation in the
TCGA data (p = 0.0018, 0.0229, and 0.0230, respectively) (Figure 3B), suggesting that they have the most
robust association with African ancestry that transcends admixture in races. We further investigated
the clinical association of the most significant candidate gene, PIM3, by evaluating its association with
survival, race, and subtype (Figure 3C–F). Higher expression of PIM3 was protective for AAs and in
the basal-like 1 subtype of TNBC. This paradox in expression vs. survival for PIM3 underscores the
need for additional biological validations and contextual information to determine genetic ancestry in
addition to molecular TNBC subtyping.
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Figure 3. African ancestry-associated genes that are current drug targets in cancer treatments show
different survival outcomes between SRR groups and breast cancer subtypes. (A) Gene expression
levels between QGA differentially expressed genes identified as drug targets between SRR CAs and
AAs in our TNBC dataset. (B) Gene expression levels between QGA differentially expressed genes in
Figure 3A, but from the TCGA cohort. (C) Relapse-free survival curve of PIM3 for SRR AAs shows that
higher expression of PIM3 is associated with higher probability of relapse-free survival (p = 0.051). (D)
Relapse-free survival curve for PIM3 for SRR CAs shows that higher expression of PIM3 is associated
with lower probability of relapse-free survival (p = 0.11). (E) Relapse-free survival curve of PIM3 for
TNBC basal-like 1 tumors shows that higher expression of PIM3 is associated with higher probability
of relapse-free survival (p = 0.0051). (F) Relapse-free survival curve of PIM3 for TNBC mesenchymal
tumors shows that higher expression of PIM3 is associated with lower probability of relapse-free
survival (p = 0.24).
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Table 1. Genes involved in networks with African ancestry-associated genes are potential therapeutic/disease management targets with currently utilized treatments.
Gene Name Drugs Tested in Cancer Disease (Cancer or Other) Organism Pubmed ID (PMID)
AKT1 AKT Serine/Threonine Kinase 1
Arsenic Trioxide,
Carboplatin, Everolimus,
Cisplatin, Nelfinavir
Various Cancers Human 12480548
CCND1 Cyclin D1
Arsenic Trioxide,
Cetuximab, Aspirin,
Trametinib, Palbociclib
Various Cancers and other
diseases Human 12480548
SLC12A2 Solute Carrier Family 12 Member2
Bumetanide and
Furosemide
Neonatal Seizures, Autism, Heart
Failure Human 11698253
PPP2R4 Protein Phosphatase 2Phosphatase Activator Ceramide Breast Cancer, Diabetes, Obesity Human 29261144
RELA RELA Proto-Oncogene, NF-KBSubunit Dimethyl fumarate Multiple Sclerosis Human 26683377
CITED4
Cbp/P300 Interacting
Transactivator With Glu/Asp Rich
Carboxy-Terminal Domain 4
Fluorouracil Cardiac ischaemia/reperfusion(I/R) injury Mouse 28304151
PIM3 Pim-3 Proto-Oncogene,Serine/Threonine Kinase
Fostamatinib, Gefitinib,
Sunitinib, Ruboxistaurin Cancer and others Human 26516587
EGFR Epidermal Growth FactorReceptor
Gefitinib, Erlotinib,
Lapatinib and Cetuximab Non-small cell lung cancer Human 15118073
LPL Lipoprotein Lipase Orlistat, Fenofibrate Obesity and Diabetes Human 24016212
NUDC Nuclear Distribution C, DyneinComplex Regulator Phenethyl Isothiocyanate
Various Cancers and
Cardiovascular Disease Human 21838287
MEPCE Methylphosphate CappingEnzyme S-Adenosyl methionine Various Human 23985780
IL6 Interleukin 6 Siltuximab, Vitamin C andE, Adalimumab Various Human 8823310
NFKB1 Nuclear Factor Kappa B Subunit 1 Thalidomide, Donepezil,Glycyrrhizin, Triflusal Various Human 15723633
ADAMTS4 ADAM Metallopeptidase withThrombospondin Type 1 Motif 4 Tinzaparin
Brain Tumors,
Thromboembolism, Thrombosis Human 15723278
TP53 Tumor Protein P53
Venetoclax,
Cyclophosphamide,
Fluorouracil, Cisplatin
Various Human 27069256
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3. Discussion
TNBC, the most aggressive form of breast cancer, has limited treatment options. It is characterized
by poor overall survival, with recurrent, distant metastatic disease common within the first three years
after aggressive chemotherapy treatment. TNBC disproportionally affects young AA women, and
there is increasing evidence that this disparity cannot be attributed to solely to SES and lack of access to
care. Our previous studies [14,45,46] and others [47] have demonstrated differences in gene expression
based upon race. However, since SRR does not allow more than correlation with African ancestry,
Quantified Genetic Ancestry (QGA) analyses are needed to understand the shared genetic drivers of
TNBC observed across the modern African Diaspora [6,48]. Furthermore, due to the heterogenicity of
TNBC, additional tools are required to define TNBC subtypes and ancestry-related differences within
TNBC subtypes. Herein, we used two newly developed tools to evaluate the heterogeneity of TNBC
for patients with African ancestry.
Prior studies that compare SRR groups for differential gene expression in breast and other cancers
have revealed significant differences between AA and EA race groups [14,45–47]; however, many
of these changes are confounded by genetic admixture and non-genetic factors that prevent clear
interpretation of genetic contributions to SRR differences in tumor biology. By use of QGA, we
identified ancestry-related differential expression of genes in treatment-naïve and residual TNBC
tumors which were involved in canonical cancer pathways, but had predictions of modified functional
activity. This deconvolution of ancestry has also been employed in prostate cancers, also revealing gene
expression correlated with specific West African ancestry [49]. We observed that specific pseudogenes,
that showed reduced levels of expression associated with African ancestry, are located in regions
of the genome that are frequently deleted in sporadic breast and prostate tumors derived from AA
patients [50]. An example of this expression/deletion effect involves a pseudogene, RNU2-6p, which is
downregulated in AA TNBCs (Figure S6). According to GTEx data, this gene is not typically expressed
in normal breast tissue; however, it is highly expressed in breast tumors within our cohort, but with
significantly reduced expression in untreated TNBC tumor of patients with significant African ancestry.
The functional relevance of this distinction, based on in silico analyses and previously published
findings [51,52], is that RNU2-6p appears to be a non-coding nuclear RNA that has a secondary structure
resembling splicing machinery. This ancestry-associated pseudogene may affect exon usage and/or
isoform splicing, which may contribute to unique molecular signatures in gene expression, translating
into disease progression in African Americans with breast cancer, as has been previously shown in
prostate cancer [53,54].
When we compared the differential genes identified by QGA with those identified by SRR, we
found a 51% overlap of ancestry-associated genes in the race-associated category. This indicates that
using SRR categories for differential gene expression can diminish ancestry-related expression, given
the convolution of admixture in race groups, and SRR categories will incorporate additional factors
that drive differences in gene expression that are independent of genetic ancestry. This also explains
the relatively larger number of differentially expressed genes associated with SRR, as opposed to
genetic ancestry, and provides additional opportunities to discern the multiple factors connected to
race/ethnicity that contribute to differential gene expression among race groups.
Additionally, despite the limited number of residual tumors in our cohort, we also observed a
robust 13-gene expression pattern upregulated in AAs but not in EAs with residual tumors. Of note,
EGFR, which is upregulated in African American breast and prostate cancers [55,56], appears to be a
driver within this gene signature. Additionally, genes that are downregulated in AAs had a strong
expression in EA patients. These differences did not correlate with TNBC subtypes as determined by
use of either the Vanderbilt or TNHF subtyping tools, suggesting that these genes are likely due to
genetic ancestry. Furthermore, in the TNHF analysis, there were fewer unclassified AA patients. This
has prognostic implications, since, for TNBCs, residual disease after neoadjuvant chemotherapy is
associated with worse overall survival relative to that for non-TNBC patients, which is not the situation
when patients achieve a complete pathologic response [57–59]. Thus, identification of genes that are
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drivers in residual tumors can help in developing targeted adjuvant therapies that could improve
survival in this patient population, for which there currently exists no effective standard of care.
The TNBC Vandy BL1/2 distribution between SRR groups was different from our previous findings
in TCGA analyses [14], likely because of inclusion all six TNBC subtype categories in that previous
study. Specifically, reassignment of IM- and MSL-retired subtypes calls resulted in redistribution of
tumors into sub-optimal categories, shifting the observed proportions of subtypes in SRR from our
previous studies (Figure 2A). This contradiction compelled us to ensure that the categorization of
subtypes was an accurate interpretation of the biological variation across TNBC tumors, and not just a
reflection of an improperly stratified training set. Our pilot utilization of the novel TNHF method, an
augmented extension of the Vanderbilt tool, is distinctive in various ways. First, TNHF reports only
the correlation scores for valid TNBC categories. Second, TNBC categories from TNHF are assigned
as a semi-quantified ‘status’, which represents the presence/absence of a mixture of valid Vanderbilt
TNBC subtypes within tumors, which corresponds to heterogeneity observed in TNBC tumors.
Because this TNHF method allows us to account for subtype heterogeneity within a tumor—denoted
as positive or negative annotations—this dynamic output allows for a comprehensive account of
proportions of TNBC subtype signatures that may be more informative for clinical management of
breast tumors. This can be transformative in TNBC disease outcomes, as certain TNBC subtypes
exhibit a higher risk of recurrence and/or drug resistance. Therefore, information of mixed tumor types
may help predict adverse outcomes or limited treatment response and tumor evolution in the context
of residual tumor behavior. In our cohort, African ancestry patients had a higher rate of basal-like 2
positive/basal-like 1 negative (BL2+/BL1−) TNBC subtypes, which is similar to previous findings for
AA patients [14,47]. This positive/negative integration of all potential TNBC categories, which have
prognostic value, has added clinical utility, particularly for making treatment decisions. The capacity
of gene expression profiles to predict treatment response is supported by clinical trial data showing
differences in pathological complete responses based upon Vanderbilt TNBC subtypes [60–62]. For
example, in the GEICAM/2006-03 TNBC neoadjuvant chemotherapy clinical trial, the best responders
were in the BL1 group, with 60% of patients achieving a pathologic complete response compared
to 20% in the LAR and IM groups [60]. Thus, use of the more refined TNHF subtyping tool, which
can provide information such that a tumor is equally BL2+ and M+, can have a greater impact on
neoadjuvant treatment decisions and can inform subsequent choices if standard treatments fail.
Both BL2/BL1 subtypes are also associated with immune gene signatures for AA TNBC
patients [14,63,64], which appears to be driven by IL-6 and TP53 signaling as determined by IPA. Both
IL-6 [65] and p53 activation [66–70] are associated with African American tumors, validating the
robustness of our analysis tools. Although we found no significant associations with Tumor Associated
Leukocyte (TAL) scores, most likely due to samples being isolated from macro-dissected regions
enriched for tumor cells and depleted of stromal and/or highly infiltrated regions, tumors of patients
with significant African ancestry corresponded with lower TAL score compared to patients with
predominantly European ancestry among treatment-naïve patients. In the tumor microenvironment,
various genes, including immunological genes, are differentially expressed by race/ethnicity [46,71].
However, some studies that utilize public datasets that have low representation of ethnic groups
indicate that immunological differences in TNBCs are relatively small [72]. Although, at the individual
level, we found a difference in lymphocytic infiltration, it was not obvious at the race/ethic group
level, may be due to small sample numbers in each race/ethnic group. However, higher TAL scores for
EAs and lower TAL scores for treated, residual tumors were noted. A TNBC study of south Asian
patients has reported increased infiltration of T-lymphocytes [73] and suggest that TNBCs with higher
immunogenicity may be candidates for immunotherapy [74]. Thus, higher TAL scores observed in our
EA TNBC patient cohorts could be exploited to select the relevant immunotherapies.
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4. Materials and Methods
4.1. TNBC Patient Cohort and Sample Collection
To identify molecular signatures that differ between TNBCs of AA women and EA women, we
performed RNA sequencing (RNAseq) on a TNBC cohort. A retrospective convenient formalin-fixed,
paraffin-embedded (FFPE) archival tissue cohort from the Division of Anatomic Pathology of University
of Alabama at Birmingham (UAB) consisting of 104 AA and EA women diagnosed with TNBC between
2000 and 2012 was selected for this study (Figure S1A). All samples were collected and utilized in
this study with the prior approval of the UAB Institutional Review Board (IRB number: 060911009).
Personal medical history and clinical records were limited for this cohort. Following quality control
screening, a final set of 75 cases remained (42 AAs and 33 EAs). Of these, samples were separated by
treatment status treatment-naïve (n = 60) or residual tumors (n = 15). Of the treatment-naïve cases,
there was a near equal distribution of race categories (31 AAs and 29 EAs). Of the residual tumor cases,
the representation of AAs was more than twice that of EA (11 AAs and four EAs). All tumors and
corresponding normal regions were macro-dissected by pathologists prior to RNA extraction. Stage
and grade distribution were similar between race groups (Table S3).
4.2. RNA Extraction, Library Preparation, and Primary Analysis
RNA was extracted from macro-dissected samples using standard RNA extraction kits. The
concentration and integrity of the RNA was estimated by a Qubit®2.0 Fluorometer (Invitrogen,
Carlsbad, CA, USA) and an Agilent 2100 Bioanalyzer (Applied Biosystems, Carlsbad, CA, USA),
respectively. Total RNA from each sample was taken into RNAseq applications. First, ribosomal
RNA (rRNA) was removed with Ribo-Zero™ Gold kits (Epicenter, Madison, WI, USA) by the
manufacturer’s recommended protocol. Then, the RNA was fragmented and primed for the first-strand
synthesis using the NEBnext First Strand synthesis module (New England BioLabs Inc., Ipswich,
MA, USA). Second-strand synthesis was then performed with the NEBnext Second Strand synthesis
module. Following this, the samples were taken into a standard library preparation protocol using
NEBNext®DNA Library Prep MasterMix Set for Illumina®with slight modifications. Briefly, end-repair
was accomplished, followed by A-tailing and custom adapter ligation. Post-ligated materials were
individually barcoded with unique in-house Genomics Service Laboratory (GSL) primers. Library
quantity was assessed with a Qubit 2.0 Fluorometer, and the library quality was estimated by utilizing
a DNA 1000 chip on an Agilent 2100 Bioanalyzer. Quantification of the final libraries for sequencing
applications was determined using qPCR-based KAPA Biosystems Library Quantification kits (Kapa
Biosystems, Inc., Woburn, MA). Paired-end sequencing was performed with an Illumina HiSeq2500
sequencer (Illumina, Inc., San Diego, CA, USA).
4.3. Quality Control and Sequence Alignment
Fast QC (version 0.11.8) was used to perform quality control on the raw sequencing reads [75].
To proceed through the analysis with high-quality reads, adapters and low-quality sequences were
trimmed from the raw reads using Trimmomatic (version 0.36) [76]. These reads were then aligned to
the reference genome (GRCh37 assembly) using HISAT2 (version 2.0.4) [77]. Although rRNA reduction
steps were taken during library preparation, we removed any remaining rRNA contamination in
the samples using the Bed-tools (version 2.26.0) intersect function against a bed file of annotated
rRNA sequences [78]. Following quality assessment of sequence data, 28 cases were excluded due to
sequencing artifacts (Figure S1B).
4.4. Gene Expression Quantification and Differential Gene Expression Analyses
After alignment and rRNA gene reads removal, RNAseq alignments were assembled into
potential transcripts, and gene expression levels were quantified using Stringtie (version 1.3.3) [77]. All
comparative analyses for differential gene expression were conducted within the respective treatment
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groups, treatment-naïve or residual tumors. To identify genes that were ancestry-associated, we used
JMP®Version 14.0 (SAS Institute Inc. Cary, NC, USA) to conduct a gene-by-gene linear regression model,
testing the quantified (continuous) measurements of African and/or European genetic ancestry against
the gene expression levels. False-discovery Rate (FDR) adjusted p-values were used to determine
significant associations. DESeq2 was then used to validate whether genetic ancestry-associated genes
were differentially expressed between self-reported AA and EA individuals [79]. Fold-change values
from both the ancestry-associated gene lists and SRR gene lists were used in IPA (see below).
4.5. TNHF TNBC Subtyping
To determine the prevalence of TNBC subtypes in the cohort, we first utilized the Vanderbilt TNBC
subtyping tool to identify basal-like 1 and 2 (BL1 and BL2), immunomodulary (IM), luminal androgen
receptor (LAR), mesenchymal (M), and mesenchymal stem-like (MSL) tumor samples [41,42]. These
six subtypes were further refined to four TNBC subtypes, with re-assignment of IM and MSL subtypes,
as these are primarily composed of immune and stromal cell populations, respectively [43]. To address
this in our variant calls from the Vanderbilt TNBC type tool, samples that were assigned IM or MSL
were re-assigned to their second most correlated TNBC subtype. As a supplementary validation
method to the Vanderbilt TNBC classification tool, a summarized ranks measure was computed using
the original TNBC subtype signatures for all samples using normalized RNAseq expression data.
TNBC subtype signatures were obtained from Lehmann et al. [41]. Across all samples, genes were
ranked from low to high expression using the rank function in R statistical software with the minimum
rank method used to resolve duplicate expression ties. For each sample, ranks for each gene in the
given subtype signature were extracted, and a representative median or mean of ranks for the gene
signature was calculated to estimate the overall regulation of the signature with respect to the total
expression. The TNBC subtype signature with max median or mean signature rank per sample was
the assigned TNBC subtype for the sample. Where max median or mean rank was used, it is denoted
in figures as TNHF-Median or -Mean, respectively.
4.6. Genetic Ancestry and Admixture Estimations from RNAseq Single Nucleotide Variants (SNV)
Genetic ancestry was determined using Admixture (version 1.3.0) [80], which provides a maximum
likelihood estimation of individual ancestries from multi-locus SNVs. Prior to admixture analysis,
GATK best practices were used to identify SNVs from the RNAseq reads. Specifically, we aligned
our RNAseq reads to hg19 using STAR (version 2.5.2b) [81]. Variants were called using GATK
HaplotypeCaller (version 3.8) [82,83] and subsequently filtered to exclude rare variants (i.e., <5%
across all phase 3,1000 genomes), all INDELs, and any SNPs that were not biallelic. Ancestral reference
populations were based on the 1000 Genomes Project phase 3 superpopulations [84].
4.7. Gene Network Analyses
To complete in silico analysis of predicted gene interactions and enrichment of functional pathways,
we utilized IPA software (version 01-16) (QIAGEN Inc., https://www.qiagenbioinformatics.com) to
analyze the ancestry-associated and SRR differentially expressed gene lists [40]. After uploading
each respective dataset, we filtered out any differentially expressed gene that was not significant at
a threshold of p < 0.05. In the core analysis, IPA takes in the differential expression data and uses
the log-fold expression change values in coordination with the curated Ingenuity Knowledge Base to
identify top signaling and metabolic pathways, upstream regulator molecules, and associations with
various diseases and bio-functions. Significance of networks was based on the score (where a score of
≥ 3 indicates with > 99% confidence that the network was not generated by random chance).
4.8. Estimation of Tumor-Associated Leukocyte Populations
The CIBERSORT [44] online platform was used to determine the estimated abundance of
tumor-associated immune cells in our tumor samples. The analysis was completed with 500
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permutations, and quantile normalization was disabled, as recommended for RNAseq data input.
The absolute score for a given tumor-associated leukocyte (TAL) population represents the estimated
abundance of immune cell types in the tumor sample. The CIBERSORT absolute score represents the
abundance of all 22 tumor-associated leukocyte (TAL) populations scored as identified by the tool.
TAL absolute scores were dichotomized into low and high categories using lower-quantile distribution.
4.9. Survival Analyses
Kaplan–Meier Plotter (KMPLOT) [85,86] was used to determine gene expression-associated
survival outcomes. Our analysis was based on the version of data available (last accessed 12/2019).
To determine the association between survival outcomes and PIM3 gene expression within SRR race
groups, we used the KMPLOT TCGA pan-cancer breast cohort platform [86]. Relapse-free survival
curves were calculated comparing low versus high PIM3 expression among AA (n = 153) and EA
(n = 658) groups. To determine association of survival outcomes and PIM3 gene expression among
TNBC subtype groups, we used the Kaplan–Meier Plotter breast cancer platform, which included TNBC
cases from a collection of 35 GEO datasets provided through the KMPlot.com analysis platform [85].
Relapse-free survival curves comparing low versus high PIM3 expression were assessed among BL1
(n = 105) and M (n = 101). Hazard ratios and p-values are reported in the figure panels for each survival
analysis. The auto-select best cutoff option was used to determine the cut-off for high versus low PIM3
expression within each analysis group in both tools. For each analysis, this considers all cutoff values
between the lower and upper quartiles for PIM3 expression, and selects the best performing value to
distinguish high verses low expression. Numbers of PIM3 high- versus low-expressing individuals at
each time interval (in months) is shown as survival tables within each KM plot.
5. Conclusions
Genes that exhibit ancestry-specific regulation, particularly those with cancer-related function, are
a valuable resource from our findings. Pointedly, targeted therapeutics that are presently undergoing
clinical trials or have received FDA approval match several of our ancestry-associated genes that
were differentially expressed in our cohort. Further validation of these genes’ differential expression
between race groups in the Breast Cancer TCGA RNAseq cohort demonstrates the reliability of our
findings and the likelihood of translational impact. Of note, in both cohorts we found higher levels
of PIM3 and PPP2RA in TNBC tumors from African-American patients. However, in independent
validation cohorts from GEO and TCGA, survival analyses indicated that high expression correlated
with divergent clinical outcomes between race groups, as high PIM3 expression correlated with better
survival for patients of African ancestry, compared with a worse overall survival for the EA patients.
Limitations to stratify public data with correlated demographic data and missing survival data in our
cohort preclude definitive actionable clinical conclusions at this time. Although there are ongoing
efforts to recruit minorities into existing clinical trials [87,88], these findings highlight the impactful
possibilities of utilizing genetic ancestry in multi-ethnic cohorts and the need to demonstrate that
variation within and among TNBC subtypes and how genetic ancestry may impact tumor biology,
which in could guide treatment decisions.
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